Retatrutide 10mg
99.682% HPLC PurityA triple GLP-1, GIP and glucagon receptor agonist, supplied as a 10mg lyophilised vial.

SKU: PEP-039-10MG
A long-acting amylin analogue, supplied as a 10mg lyophilised vial. Research use only. Preorder — ships with the first batch.
Read the full description ↓Price includes GST
✓Free shipping on orders over $250 AUD
✓Australia Post tracked — Standard $12.99 / Express $18.99
✓Preorder: dispatched once the next batch arrives, tracked with Australia Post
A triple GLP-1, GIP and glucagon receptor agonist, supplied as a 10mg lyophilised vial.
The same triple receptor agonist as our 10mg vial, supplied at double the strength.
The same triple receptor agonist as our 10mg vial, supplied at triple the strength.
A long-acting amylin analogue, supplied as a 10mg lyophilised vial.
Research has explored amylin and calcitonin receptor signalling, including its pairing with GLP-1 agonists in preclinical studies.
This product is currently available to preorder and ships once the first batch has been produced and tested. Strictly for in-vitro laboratory research only.
A long-acting amylin analogue, supplied as a 10mg lyophilised vial. Research has explored amylin and calcitonin receptor signalling, including its pairing with GLP-1 agonists in preclinical studies. All use is strictly for in-vitro laboratory research only.
This product is a preorder. It is not held in stock yet and ships with the first batch; you will be emailed when your order is dispatched.
Batch testing documentation is published for each batch once it has been produced and tested. Contact us before ordering if you need it first.
Store lyophilised product at −20°C, protected from light and moisture, and avoid repeated freeze-thaw cycles.
No. Cagrilintide is supplied for in-vitro laboratory research only and is not approved for human consumption or therapeutic use. Scheduling attaches to the substance and changes over time; verify the current status against the TGA Poisons Standard.
Cagrilintide 10mg is sold strictly for in-vitro laboratory and research purposes only. This product is not intended for human consumption, therapeutic use, cosmetic use, or veterinary application. It has not been evaluated by the Therapeutic Goods Administration (TGA) or any other regulatory body for human use. You must be 18 years of age or older to purchase. By purchasing, you confirm that you are a qualified researcher and will use this product in compliance with all applicable Australian laws and regulations.
No questions yet — be the first to ask about this product.
Recent peer-reviewed studies from PubMed related to Cagrilintide. Provided for research context — not medical advice.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies MJ, Bajaj HS, Broholm C, et al. · The New England journal of medicine · 2025
PMID: 40544432
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW, Erichsen L, Francisco AM, et al. · Lancet (London, England) · 2021
PMID: 34798060
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D'Ascanio AM, Mullally JA, Frishman WH · Cardiology in review · 2024
PMID: 36883831
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Frias JP, Deenadayalan S, Erichsen L, et al. · Lancet (London, England) · 2023
PMID: 37364590
Source: U.S. National Library of Medicine (PubMed). Citations are fetched live and cached; inclusion does not imply endorsement of any therapeutic use.